Tevogen Bio Pursues Acquisitions for $100M Annual Revenue

Tevogen Bio Holdings Inc. announced continued progress on strategic acquisition initiatives aimed at achieving long-term financial self-sufficiency and generating approximately $100 million in combined annual revenue. These initiatives include evaluating a contract research organization (CRO) and other opportunities to expand its broader healthcare platform. The company seeks to evolve into a revenue-generating enterprise comprising its biotechnology, AI, and potential healthcare services arms, with a focus on capital discipline and long-term value creation.